These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 30231307)
21. College of American Pathologists' laboratory standards for next-generation sequencing clinical tests. Aziz N; Zhao Q; Bry L; Driscoll DK; Funke B; Gibson JS; Grody WW; Hegde MR; Hoeltge GA; Leonard DG; Merker JD; Nagarajan R; Palicki LA; Robetorye RS; Schrijver I; Weck KE; Voelkerding KV Arch Pathol Lab Med; 2015 Apr; 139(4):481-93. PubMed ID: 25152313 [TBL] [Abstract][Full Text] [Related]
22. Next generation sequencing-based gene panel tests for the management of solid tumors. Nagahashi M; Shimada Y; Ichikawa H; Kameyama H; Takabe K; Okuda S; Wakai T Cancer Sci; 2019 Jan; 110(1):6-15. PubMed ID: 30338623 [TBL] [Abstract][Full Text] [Related]
23. Application of next-generation sequencing to improve cancer management: A review of the clinical effectiveness and cost-effectiveness. Tan O; Shrestha R; Cunich M; Schofield DJ Clin Genet; 2018 Mar; 93(3):533-544. PubMed ID: 29265354 [TBL] [Abstract][Full Text] [Related]
24. Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. Janku F; Zhang S; Waters J; Liu L; Huang HJ; Subbiah V; Hong DS; Karp DD; Fu S; Cai X; Ramzanali NM; Madwani K; Cabrilo G; Andrews DL; Zhao Y; Javle M; Kopetz ES; Luthra R; Kim HJ; Gnerre S; Satya RV; Chuang HY; Kruglyak KM; Toung J; Zhao C; Shen R; Heymach JV; Meric-Bernstam F; Mills GB; Fan JB; Salathia NS Clin Cancer Res; 2017 Sep; 23(18):5648-5656. PubMed ID: 28536309 [No Abstract] [Full Text] [Related]
25. Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing. Kohlmann A; Bacher U; Schnittger S; Haferlach T Leuk Lymphoma; 2014 Aug; 55(8):1725-34. PubMed ID: 24144312 [TBL] [Abstract][Full Text] [Related]
26. Considerations of developing an NGS assay for clinical applications in precision oncology: The NCI-MATCH NGS assay experience. Lih CJ; Takebe N Curr Probl Cancer; 2017; 41(3):201-211. PubMed ID: 28625332 [TBL] [Abstract][Full Text] [Related]
27. More Pitfalls Related to Next-generation Sequencing (NGS). Sorscher S Am J Clin Oncol; 2016 Aug; 39(4):424. PubMed ID: 27465427 [No Abstract] [Full Text] [Related]
28. The Next Generation of Molecular Pathology is Here: Validation of Next-Generation Sequencing Technology for Clinical Molecular Testing Across Multiple Different Disciplines. Weck KE Arch Pathol Lab Med; 2017 Jun; 141(6):749-750. PubMed ID: 28557596 [No Abstract] [Full Text] [Related]
29. Analysis of the whole mitochondrial genome: translation of the Ion Torrent Personal Genome Machine system to the diagnostic bench? Seneca S; Vancampenhout K; Van Coster R; Smet J; Lissens W; Vanlander A; De Paepe B; Jonckheere A; Stouffs K; De Meirleir L Eur J Hum Genet; 2015 Jan; 23(1):41-8. PubMed ID: 24667782 [TBL] [Abstract][Full Text] [Related]
30. Clinical Trial Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a Non-National Cancer Institute-Designated Cancer Program. Mantripragada KC; Olszewski AJ; Schumacher A; Perez K; Birnbaum A; Reagan JL; Mega A; Khurshid H; Bartley C; Lombardo A; Rossiter R; Papa A; Bakalarski P; Safran H J Oncol Pract; 2016 Apr; 12(4):e396-404. PubMed ID: 26907448 [TBL] [Abstract][Full Text] [Related]
31. Next-generation sequencing-based clinical sequencing: toward precision medicine in solid tumors. Wakai T; Prasoon P; Hirose Y; Shimada Y; Ichikawa H; Nagahashi M Int J Clin Oncol; 2019 Feb; 24(2):115-122. PubMed ID: 30515675 [TBL] [Abstract][Full Text] [Related]
32. Mutation Yield of a 34-Gene Solid Tumor Panel in Community-Based Tumor Samples. Sanders H; Qu K; Li H; Ma L; Barlan C; Zhang X; Prentice J; Wolfson D; Crossley B; Sferruzza A; Sninsky J; Ross D; Grupe A; Catanese J; Hantash F; Waldman F Mol Diagn Ther; 2016 Jun; 20(3):241-53. PubMed ID: 27084556 [TBL] [Abstract][Full Text] [Related]
33. Comparison of Next-Generation Sequencing Panels and Platforms for Detection and Verification of Somatic Tumor Variants for Clinical Diagnostics. Misyura M; Zhang T; Sukhai MA; Thomas M; Garg S; Kamel-Reid S; Stockley TL J Mol Diagn; 2016 Nov; 18(6):842-850. PubMed ID: 27770852 [TBL] [Abstract][Full Text] [Related]
34. Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial. Lih CJ; Harrington RD; Sims DJ; Harper KN; Bouk CH; Datta V; Yau J; Singh RR; Routbort MJ; Luthra R; Patel KP; Mantha GS; Krishnamurthy S; Ronski K; Walther Z; Finberg KE; Canosa S; Robinson H; Raymond A; Le LP; McShane LM; Polley EC; Conley BA; Doroshow JH; Iafrate AJ; Sklar JL; Hamilton SR; Williams PM J Mol Diagn; 2017 Mar; 19(2):313-327. PubMed ID: 28188106 [TBL] [Abstract][Full Text] [Related]
35. Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSP. Kim M; Shim HS; Kim S; Lee IH; Kim J; Yoon S; Kim HD; Park I; Jeong JH; Yoo C; Cheon J; Kim IH; Lee J; Hong SH; Park S; Jung HA; Kim JW; Kim HJ; Cha Y; Lim SM; Kim HS; Lee CK; Kim JH; Chun SH; Yun J; Park SY; Lee HS; Cho YM; Nam SJ; Na K; Yoon SO; Lee A; Jang KT; Yun H; Lee S; Kim JH; Kim WS Cancer Res Treat; 2024 Jul; 56(3):721-742. PubMed ID: 38037319 [TBL] [Abstract][Full Text] [Related]
36. Testing NTRK testing: Wet-lab and in silico comparison of RNA-based targeted sequencing assays. Pfarr N; Kirchner M; Lehmann U; Leichsenring J; Merkelbach-Bruse S; Glade J; Hummel M; Stögbauer F; Lehmann A; Trautmann M; Kumbrink J; Jung A; Dietmaier W; Endris V; Kazdal D; Evert M; Horst D; Kreipe H; Kirchner T; Wardelmann E; Lassen U; Büttner R; Weichert W; Dietel M; Schirmacher P; Stenzinger A Genes Chromosomes Cancer; 2020 Mar; 59(3):178-188. PubMed ID: 31652375 [TBL] [Abstract][Full Text] [Related]
37. Clinical Genomic Profiling of a Diverse Array of Oncology Specimens at a Large Academic Cancer Center: Identification of Targetable Variants and Experience with Reimbursement. Sireci AN; Aggarwal VS; Turk AT; Gindin T; Mansukhani MM; Hsiao SJ J Mol Diagn; 2017 Mar; 19(2):277-287. PubMed ID: 28024947 [TBL] [Abstract][Full Text] [Related]
38. Assessing the Cost-Effectiveness of Next-Generation Sequencing as a Biomarker Testing Approach in Oncology and Policy Implications: A Literature Review. Mirza M; Goerke L; Anderson A; Wilsdon T Value Health; 2024 Sep; 27(9):1300-1309. PubMed ID: 38729563 [TBL] [Abstract][Full Text] [Related]
39. One byte at a time: evidencing the quality of clinical service next-generation sequencing for germline and somatic variants. Gutowska-Ding MW; Deans ZC; Roos C; Matilainen J; Khawaja F; Brügger K; Ahn JW; Boustred C; Patton SJ Eur J Hum Genet; 2020 Feb; 28(2):202-212. PubMed ID: 31570784 [TBL] [Abstract][Full Text] [Related]
40. ICO amplicon NGS data analysis: a Web tool for variant detection in common high-risk hereditary cancer genes analyzed by amplicon GS Junior next-generation sequencing. Lopez-Doriga A; Feliubadaló L; Menéndez M; Lopez-Doriga S; Morón-Duran FD; del Valle J; Tornero E; Montes E; Cuesta R; Campos O; Gómez C; Pineda M; González S; Moreno V; Capellá G; Lázaro C Hum Mutat; 2014 Mar; 35(3):271-7. PubMed ID: 24227591 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]